Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study

Ähnliche Einträge

• Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer
  von: Tae Seung Lee, et al.
  Veröffentlicht: (2025)
• When Matching Misses the Mark: Reassessing Capecitabine's Reported Benefit in Resected Biliary Tract Cancer
  von: Raza ur Rehman, et al.
  Veröffentlicht: (2025)
• Efficacy and Safety of Low‐Dose Oral Etoposide Combined With Capecitabine for Patients With Postoperative Metastatic Breast Cancer Resistant to Anthracycline/Taxanes
  von: Xue Chen, et al.
  Veröffentlicht: (2025)
• Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
  von: Zhengfeng Xuan, et al.
  Veröffentlicht: (2025)
• Postoperative Adjuvant Therapy in Resectable Advanced Oral Squamous Cell Carcinoma With Intermediate Risk Factors
  von: Koichi Koizumi, et al.
  Veröffentlicht: (2025)